EPHB1 and meningioma: In NF2-null meningioma cell lines, kinome profiling revealed activation of Eph receptor tyrosine kinases (EphA2, EphB1), c-KIT, and the Src/SFK pathway, targets of the FDA-approved kinase inhibitor Dasatinib.